Goldman Sachs Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)

Goldman Sachs analyst Asad Haider reiterated a Buy rating on Johnson & Johnson today and set a price target of $275.00.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Haider is a 4-star analyst with an average return of 19.5% and a 75.68% success rate. Haider covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Merck & Company.

In addition to Goldman Sachs, Johnson & Johnson also received a Buy from Wells Fargo’s Larry Biegelsen in a report issued today. However, on the same day, Barclays reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ).

Based on Johnson & Johnson’s latest earnings release for the quarter ending December 28, the company reported a quarterly revenue of $24.56 billion and a net profit of $5.12 billion. In comparison, last year the company earned a revenue of $22.52 billion and had a net profit of $3.43 billion

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year. Most recently, in February 2026, Timothy Schmid, the EVP, WW Chair, MedTech of JNJ sold 1,322.00 shares for a total of $324,762.52.